Can lurbinectedin cause lasting neurological side effects?

Can lurbinectedin cause lasting neurological side effects?

Lurbinectedin is a synthetic alkaloid derived from sea squirts that works by binding DNA minor grooves and interfering with transcription factors. It is approved for relapsed small cell lung cancer after platinum-based chemotherapy.

What neurological side effects occur during treatment?

Patients in clinical trials reported fatigue, headache, and peripheral neuropathy. Peripheral neuropathy occurred in about 10% of patients, often as numbness or tingling in the hands and feet. Fatigue was more common, reported by roughly 50% of patients. Fatigue and neuropathy both appeared at all dose levels and occurred after fewer than 10 cycles in most cases.

What happens if the side effects persist after stopping treatment?

Data on long-term neurological outcomes after discontinuation remain limited. In the PM1183-B-003-14 study, neuropathy resolved in some patients after stopping lurbinectedin. In others, symptoms persisted at reduced severity. Data on true permanence are not publicly reported.

How does lurbinectedin compare with topotecan?

Lurbinectedin produced lower rates of peripheral neuropathy than topotecan. Topotecan caused neuropathy in 17% of patients, while lurbinectedin produced it in 10%. Fatigue rates were similar. Lurbinectedin also showed less overall toxicity than topotecan in the head-to-head portion of the trial.

When does the lurbinectedin patent expire?

The basic compound patent expires in the United States in 2034. DrugPatentWatch.com